|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THAP2 |
Gene summary for THAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THAP2 | Gene ID | 83591 |
| Gene name | THAP domain containing 2 | |
| Gene Alias | THAP2 | |
| Cytomap | 12q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9H0W7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83591 | THAP2 | LZE4T | Human | Esophagus | ESCC | 1.02e-06 | 2.71e-01 | 0.0811 |
| 83591 | THAP2 | P1T-E | Human | Esophagus | ESCC | 5.25e-05 | 1.49e-01 | 0.0875 |
| 83591 | THAP2 | P2T-E | Human | Esophagus | ESCC | 1.12e-24 | 3.86e-01 | 0.1177 |
| 83591 | THAP2 | P4T-E | Human | Esophagus | ESCC | 1.58e-11 | 3.80e-01 | 0.1323 |
| 83591 | THAP2 | P5T-E | Human | Esophagus | ESCC | 2.52e-15 | 1.76e-01 | 0.1327 |
| 83591 | THAP2 | P8T-E | Human | Esophagus | ESCC | 1.64e-12 | 2.55e-01 | 0.0889 |
| 83591 | THAP2 | P9T-E | Human | Esophagus | ESCC | 3.02e-06 | 1.48e-01 | 0.1131 |
| 83591 | THAP2 | P10T-E | Human | Esophagus | ESCC | 3.37e-18 | 2.51e-01 | 0.116 |
| 83591 | THAP2 | P12T-E | Human | Esophagus | ESCC | 9.03e-16 | 1.96e-01 | 0.1122 |
| 83591 | THAP2 | P15T-E | Human | Esophagus | ESCC | 4.54e-06 | 1.73e-01 | 0.1149 |
| 83591 | THAP2 | P16T-E | Human | Esophagus | ESCC | 1.50e-10 | 9.80e-02 | 0.1153 |
| 83591 | THAP2 | P17T-E | Human | Esophagus | ESCC | 6.36e-03 | 1.64e-01 | 0.1278 |
| 83591 | THAP2 | P20T-E | Human | Esophagus | ESCC | 1.74e-15 | 4.88e-01 | 0.1124 |
| 83591 | THAP2 | P21T-E | Human | Esophagus | ESCC | 1.39e-17 | 3.52e-01 | 0.1617 |
| 83591 | THAP2 | P22T-E | Human | Esophagus | ESCC | 3.86e-03 | 9.98e-02 | 0.1236 |
| 83591 | THAP2 | P23T-E | Human | Esophagus | ESCC | 1.03e-16 | 5.41e-01 | 0.108 |
| 83591 | THAP2 | P24T-E | Human | Esophagus | ESCC | 4.18e-08 | 1.15e-01 | 0.1287 |
| 83591 | THAP2 | P26T-E | Human | Esophagus | ESCC | 1.52e-10 | 2.15e-01 | 0.1276 |
| 83591 | THAP2 | P27T-E | Human | Esophagus | ESCC | 4.39e-11 | 2.82e-01 | 0.1055 |
| 83591 | THAP2 | P28T-E | Human | Esophagus | ESCC | 1.68e-12 | 2.08e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THAP2 | SNV | Missense_Mutation | novel | c.115G>T | p.Val39Phe | p.V39F | Q9H0W7 | protein_coding | tolerated(0.11) | possibly_damaging(0.48) | TCGA-D8-A1JB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| THAP2 | deletion | Frame_Shift_Del | novel | c.243delN | p.Cys83ValfsTer4 | p.C83Vfs*4 | Q9H0W7 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| THAP2 | SNV | Missense_Mutation | rs183448616 | c.122G>A | p.Arg41His | p.R41H | Q9H0W7 | protein_coding | deleterious(0) | benign(0.071) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| THAP2 | SNV | Missense_Mutation | rs776220464 | c.109N>T | p.Arg37Cys | p.R37C | Q9H0W7 | protein_coding | tolerated(0.07) | benign(0.013) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| THAP2 | SNV | Missense_Mutation | c.169T>A | p.Phe57Ile | p.F57I | Q9H0W7 | protein_coding | deleterious(0.01) | benign(0.385) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| THAP2 | SNV | Missense_Mutation | novel | c.652N>A | p.Leu218Ile | p.L218I | Q9H0W7 | protein_coding | tolerated_low_confidence(0.07) | benign(0.142) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| THAP2 | insertion | Frame_Shift_Ins | novel | c.593_594insTCCTTTGGAAGATTTTAAGA | p.Glu207TrpfsTer17 | p.E207Wfs*17 | Q9H0W7 | protein_coding | TCGA-F4-6459-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| THAP2 | SNV | Missense_Mutation | rs776220464 | c.109C>T | p.Arg37Cys | p.R37C | Q9H0W7 | protein_coding | tolerated(0.07) | benign(0.013) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| THAP2 | SNV | Missense_Mutation | novel | c.248G>A | p.Cys83Tyr | p.C83Y | Q9H0W7 | protein_coding | tolerated(0.05) | probably_damaging(0.988) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| THAP2 | SNV | Missense_Mutation | novel | c.484G>T | p.Ala162Ser | p.A162S | Q9H0W7 | protein_coding | tolerated(0.25) | possibly_damaging(0.836) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |